Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lazertinib as a frontline treatment in patients with EGFR-mutated advanced non-small cell lung cancer: Long-term follow-up results from LASER201.

Lung cancer (Amsterdam, Netherlands) - 1 Apr 2024

Chul Cho Byoung, Han Ji-Youn, Hyeong Lee Ki, Lee Yun-Gyoo, Kim Dong-Wan, Joo Min Young, Kim Sang-We, Kyung Cho Eun, Kim Joo-Hang, Lee Gyeong-Won, Sook Lee Sung, Lee NaMi, Young Wang Jang, Park Hyejoo, Ahn Myung-Ju

Abstract excerpt

OBJECTIVE: This analysis of the first-line cohort of LASER201 study evaluated the efficacy and safety of lazertinib 240 mg as a frontline therapy for epidermal growth factor receptor (EGFR)-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). METHODS: A total of 43 patients, with EGFR mutation-positive (Exon19Del, n = 24; L858R, n = 18; G719X, n = 1) locally advanced or metastatic NSCLC who...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Diarrhea

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Exanthema

Share to Morpholines

Share to Protein Kinase Inhibitors

Share to Pruritus

Share to Pyrazoles

Share to Pyrimidines

Source

Identifiers

PMID: 38432025
DOI: 10.1016/j.lungcan.2024.107509

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Lazertinib as a frontline treatment in patients with EGFR-mutated advanced non-small cell lung cancer: Long-term follow-up results from LASER201.PMID 38432025Read ↗

Lazertinib Versus Gefitinib Tyrosine Kinase Inhibitors in Treatment-Naíve Patients With EGFR-Mutated Advanced NSCLC: Analysis of the Asian Subpopulation in LASER301.Semantic proximity Read ↗

Lazertinib: on the Way to Its Throne.Semantic proximity Read ↗

Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non-Small-Cell Lung Cancer: Results From LASER301.Semantic proximity Read ↗

Updated overall survival and ctDNA analysis in patients with EGFR T790M-positive advanced non-small cell lung cancer treated with lazertinib in the phase 1/2 LASER201 study.Semantic proximity Read ↗

Real-world study of lazertinib as second-line or greater treatment in advanced non-small cell lung cancer.Semantic proximity Read ↗

Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced Non-Small Cell Lung Cancer: Results From CHRYSALIS-2.Semantic proximity Read ↗

Epidermal growth factor receptor tyrosine kinase inhibitor for the treatment of non-small cell lung cancer in the past 30 years (1997-2026).Semantic proximity Read ↗

Efficacy and Safety of Limertinib (ASK120067) in Patients With Locally Advanced or Metastatic EGFR Thr790Met-Mutated NSCLC: A Multicenter, Single-Arm, Phase 2b Study.Semantic proximity Read ↗

A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors.Semantic proximity Read ↗

Lazertinib versus Gefitinib as First-Line Treatment for EGFR-mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean Subset.Semantic proximity Read ↗

A real-world study of the efficacy and safety of furmonertinib for patients with non-small cell lung cancer with EGFR exon 20 insertion mutations.Semantic proximity Read ↗

Lazertinib in pretreated EGFR T790M-mutated advanced non-small cell lung cancer: A real-world multicenter study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.